1 40 1 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Treatment of Symptoms in Children with Q3 Conditions Scoping Review Results Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.1016/j.braindev.2008.12.010" target="_blank" rel="noreferrer noopener">http://doi.org/​10.1016/j.braindev.2008.12.010</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Clinical overview of children with mucopolysaccharidosis type III A and effect of Risperidone treatment on children and their mothers psychological status Publisher An entity responsible for making the resource available Brain and Development Date A point or period of time associated with an event in the lifecycle of the resource 2010 Subject The topic of the resource behavior problems; sleep disturbance; pharmacologic intervention; risperidone; hyperactivity Creator An entity primarily responsible for making the resource Kalkan U S; Ozbaran B; Demiral N; Yuncu Z; Erermis S; Coker M Description An account of the resource Mucopolysaccharidosis IIIA (MPS IIIA) is a lysosomal storage disorder characterized by progressive mental deterioration and severe behavioral problems. We conducted an open-label, crossover study of the efficacy and safety of Risperidone on behavioral disorder in children with MPS IIIA. A total of 12 patients (5.5 +/- 2.2 years) with enzymatic diagnosis of MPS IIIA were randomly assigned to receive Risperidone (0.125-2 mg/d) for 6 months. The hyperactivity and disruptive behavior level of children before and after treatment was evaluated regarding the scores from Turgay DSM IV Based Child and Adolescent Behavior Disorders Screening and Rating Scale (T-DSM-IV-S). Clinic Global Impression Scale - Severity (CGIS-S) was used for all cases for determining the psychiatric disorder severity. The anxiety and depression levels of mothers before and after treatment were evaluated using Hamilton Anxiety Scale (HAM-A) and Beck Depression Inventory (BDI). The adverse effects were evaluated by monitoring weight, serum prolactin, glucose and lipid levels. The response to the treatment was measured by decrease in values of CGI-S (from 6 +/- 1.12 to 2.91 +/- 0.66, p = 0.001). According to T-DSM-IV-S scores the best improvement was observed in hyperactivity scores (16.25 +/- 8.57/11.58 +/- 7.26, p = 0.001), followed by opposition/defiance (6.66 +/- 5.92/5.08 +/- 4.88, p = 0.032), and conduct disorder scores (1.00 +/- 1.85/0.41 +/- .99, p = 0.67). No clinically relevant elevations in weight and serum prolactin, glucose or lipid levels have been documented (p > 0.05). There was a significant decrease in anxiety and depression scores of mothers (HAM-A: 20.33 +/- 8.28/17.91 +/- 6.89, BDI: 23.58 +/- 7.14/20.5 +/- 5.93, p < 0.001). To our knowledge, research on the pharmacological treatment of MPS IIIA with Risperidone has not been reported. According to our data, Risperidone appeared to be safe and effective in MPS IIIA patients. © 2008 Elsevier B.V. All rights reserved. Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1016/j.braindev.2008.12.010" target="_blank" rel="noreferrer noopener">10.1016/j.braindev.2008.12.010</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s). 2010 behavior problems Brain and Development Coker M Demiral N Erermis S hyperactivity Kalkan U S Ozbaran B pharmacologic intervention Risperidone sleep disturbance Yuncu Z